What is a PDUFA date?
What a PDUFA date is
A PDUFA date is the date by which the US Food and Drug Administration aims to finish reviewing a drug or biologic application and send the company its decision. It is also called the PDUFA goal date or target action date.
The FDA’s commitment is to review and act on
an application within a set number of months. In the FDA’s own definition, acting means issuing a complete action letter after the complete review of a filed complete application
. That letter is either an approval or a complete response letter that lists what stands in the way of approval.
So a PDUFA date tells you when a decision is due. It says nothing about what the decision will be.
What PDUFA stands for
PDUFA stands for the Prescription Drug User Fee Act. Congress created it in 1992. It authorizes the FDA to collect fees from companies that submit certain human drug applications, and in return the FDA agrees to goals for how quickly it reviews them.
The law has to be renewed periodically. The current version, PDUFA VII, was signed on 30 September 2022 and runs through September 2027. Its review goals are set out in a commitment letter covering fiscal years 2023 through 2027, which is where the timelines below come from.
Standard and priority review timelines
The FDA sorts applications into two tiers. Priority review is for drugs that, if approved, would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious condition. Everything else gets standard review. The goal is to act on 90 percent of applications within these periods:
| Application | Standard review | Priority review |
|---|---|---|
| New molecular entity NDA or original BLA | 10 months from the 60-day filing date | 6 months from the 60-day filing date |
| Other original NDA | 10 months from receipt | 6 months from receipt |
| Efficacy supplement, such as a new indication | 10 months from receipt | 6 months from receipt |
| Resubmission after a complete response letter | 2 months from receipt (Class 1) or 6 months from receipt (Class 2) | |
An NDA is a new drug application and a BLA is a biologics license application. For new molecular entities and original BLAs the review clock starts at the end of a 60-day filing review that begins when the FDA receives the application. Counted from the day of submission, that puts the PDUFA date about 12 months out under standard review and about 8 months out under priority review.
Priority review shortens the timeline only. In the FDA’s words, it does not alter the scientific/medical standard for approval or the quality of evidence necessary
.
PDUFA date vs approval date
They are different things. The PDUFA date is a target for the FDA to make a decision. The approval date is the day the FDA actually approves a product, if it does.
- A decision can come before the PDUFA date. The goal is to act within the period, so the date marks its end.
- A decision can come after it. The goals cover 90 percent of applications, and a goal date can be extended.
- The decision may not be an approval. A complete response letter also counts as the FDA acting on the application.
For that reason TrialRedline’s FDA calendar lists an announced review target and a published FDA decision as separate event types, each with its own source.
Are PDUFA dates public?
Not through the FDA. The agency does not publish a calendar of pending goal dates. Under its disclosure regulation, the FDA will not publicly disclose the existence of an application
before an approval letter is sent, unless the application’s existence has already been made public.
In practice the company is the source. Sponsors often announce that the FDA has accepted an application for review, and the goal date with it, in a press release or a filing with the Securities and Exchange Commission (SEC). A company that does not disclose its date leaves no public record of it.
This is why every PDUFA date in a third-party calendar traces back to a company statement, and why it is worth opening that statement. TrialRedline takes its PDUFA dates from company filings with the SEC and links each one to the filing it came from.
Exact days and broader periods
Companies do not always give a day. Some disclose an exact PDUFA date; others say only that a decision is expected in a given month, quarter or half-year.
A calendar that turns the third quarter of 2027
into 30 September 2027 has invented a date the company never gave. TrialRedline records the period as the source states it and labels the precision, so a month or quarter stays a month or quarter. Date filters on the calendar match a partial date when its period overlaps your range.
Extensions and missed dates
Three things can happen other than an approval on or before the date.
The goal date is extended
If the company submits a major amendment to its application during the review, the FDA may extend the goal date by three months
. If the company announces the new date, that is the one to follow.
The FDA issues a complete response letter
The review ends without approval. The letter describes the deficiencies the FDA found, and the company can resubmit, withdraw or request a hearing. A resubmission starts a new review period of 2 or 6 months and therefore a new goal date. See what a complete response letter is.
The date passes without a decision
The goals are commitments for 90 percent of applications, so some reviews run late. The FDA says that if it determines a decision will not meet the target date, its regulatory project manager will promptly inform the sponsor
. Whether the public hears about it depends on the company.
Finding PDUFA dates
The TrialRedline FDA calendar lists company-disclosed PDUFA dates alongside published FDA approval decisions, complete response letters and advisory committee notices. Each entry shows the date as reported, its precision, and a link to the filing or FDA publication behind it.
The calendar covers the companies and drugs TrialRedline tracks, and an event appears only when it can be matched to its source. It is not a complete list of every pending application. Each drug page shows that drug’s FDA events next to the clinical trials studying it.
Common questions
Does a PDUFA date mean approval?
No. A PDUFA date is the date by which the FDA aims to finish its review and send a decision letter. That letter can be an approval or a complete response letter, which says the application cannot be approved in its present form.
Can a drug be approved before the PDUFA date?
Yes. The FDA’s commitment is to act within the review period, so the goal date is the end of that period, not a scheduled decision day. The agency can send its decision earlier.
Are PDUFA dates public?
The FDA does not publish a list of PDUFA dates. Its regulations generally bar it from disclosing that an unapproved application exists unless that is already public. Most PDUFA dates become public because the company announces them in a press release or a filing with the Securities and Exchange Commission.
What does PDUFA stand for?
PDUFA stands for the Prescription Drug User Fee Act, which Congress created in 1992. It lets the FDA collect fees from companies that submit certain human drug applications, and it comes with review-time goals that the FDA agrees to.
How long does an FDA review take?
For a new molecular entity or an original biologics application, the FDA’s goal is to act within 10 months of the 60-day filing date under standard review and within 6 months of the 60-day filing date under priority review. The FDA commits to meeting these goals for 90 percent of applications.
What happens if the FDA misses a PDUFA date?
A PDUFA date is a performance goal. The FDA commits to meeting its goals for 90 percent of applications, so a review can run past its date. The FDA says its regulatory project manager will tell the company promptly if a decision will not meet the target date.
Sources
Every statement on this page was checked against these primary sources on 6 October 2026. Rules and programs change, so read the source before relying on a detail.
- FDA: Prescription Drug User Fee Amendments
- FDA: PDUFA reauthorization performance goals and procedures, fiscal years 2023 through 2027 (PDF)
- FDA: Priority Review
- FDA: how a sponsor is informed about a review subject to PDUFA target dates
- 21 CFR 314.430: availability for public disclosure of data and information in an application
- 21 CFR 314.110: complete response letter to the applicant